Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Moreno said he expects that Zepbound could be used in addition to PAP or as an alternate for people who are uncomfortable ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so.” Based on SURMOUNT-5 results released last month, Zepbound was more effective in promoting weight ...

and perhaps negotiations with national health services will also make it more cost-effective than Wegovy,” Alciati continued.